Entrada Therapeutics, Inc.
TRDA
$6.91
-$0.04-0.58%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -43.10M | -17.35M | 1.13M | -14.03M | 55.03M |
| Total Depreciation and Amortization | 1.03M | 946.00K | 992.00K | 937.00K | 910.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.09M | 3.75M | 2.19M | 1.65M | 2.36M |
| Change in Net Operating Assets | 8.49M | -25.85M | -35.92M | -12.82M | -18.47M |
| Cash from Operations | -29.49M | -38.51M | -31.61M | -24.27M | 39.83M |
| Capital Expenditure | -275.00K | -1.14M | -635.00K | -639.00K | -1.05M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 34.07M | 5.93M | 54.00M | -82.29M | -23.34M |
| Cash from Investing | 33.80M | 4.78M | 53.37M | -82.93M | -24.38M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 337.00K | 350.00K | 1.40M | -- | 101.37M |
| Repurchase of Common Stock | -- | -- | -- | -11.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 337.00K | 350.00K | 1.40M | -11.00K | 101.37M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.65M | -33.37M | 23.16M | -107.20M | 116.82M |